Cardiovascular and interventional radiology · 2026
Long-Term Outcomes of Uterine Artery Embolization for Treatment of Fibroids in Women Under 40: A Retrospective Survey Study at Two Institutions with Median 16-year Follow-up.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seyferth Elisabeth R, Harrison Neil E, Shlansky-Goldberg Richard D
Аннотация
PURPOSE: To assess long-term freedom from symptom recurrence and success of entering menopause without hysterectomy for patients younger than 40 years old undergoing uterine fibroid embolization (UFE).
MATERIALS AND METHODS: Women under 40 who underwent UFE from 2001-2012 at two institutions and who participated in a telephone survey in 2024 were included. The survey assessed symptom response to UFE, need for additional procedures, and patient satisfaction with UFE.
RESULTS: 976 women underwent UFE; of these, 173 were younger than 40 at the time of UFE, and 80 of 173 (46.2%) participated in the survey. Median age at embolization was 37.2 (range 26.4-39.8) and when surveyed was 52.7 (range 43.1-61.9). 70.0% (56/80) and 18.8% (15/80) of patients reported "a lot" or "a little" symptom improvement, respectively, in the first 6 months after UFE; 11.2% (9/80) reported no change. Of those with improvement, symptoms returned in 57.7% (41/71) with median time to recurrence of 11.0 years (range 0.5-20 years). Freedom from recurrence of symptoms was 68/71 (95.8%) at 1 year, 48/71 (67.6%) at 5 years, and 36/71 (50.7%) at 10 years. Freedom from hysterectomy for recurrent symptoms was 70/71 (98.6%) at 1 year, 60/71 (84.5%) at 5 years, and 51/71 (71.8%) at 10 years. Patient satisfaction with having UFE was a median of 5 on a scale of 1-5 (5 = very satisfied).
CONCLUSION: Women under 40 who undergo UFE are likely to experience return of symptoms before menopause and may require additional procedures, yet they remain highly satisfied with the procedure.
LEVEL OF EVIDENCE: Level 4, Case Series.
MATERIALS AND METHODS: Women under 40 who underwent UFE from 2001-2012 at two institutions and who participated in a telephone survey in 2024 were included. The survey assessed symptom response to UFE, need for additional procedures, and patient satisfaction with UFE.
RESULTS: 976 women underwent UFE; of these, 173 were younger than 40 at the time of UFE, and 80 of 173 (46.2%) participated in the survey. Median age at embolization was 37.2 (range 26.4-39.8) and when surveyed was 52.7 (range 43.1-61.9). 70.0% (56/80) and 18.8% (15/80) of patients reported "a lot" or "a little" symptom improvement, respectively, in the first 6 months after UFE; 11.2% (9/80) reported no change. Of those with improvement, symptoms returned in 57.7% (41/71) with median time to recurrence of 11.0 years (range 0.5-20 years). Freedom from recurrence of symptoms was 68/71 (95.8%) at 1 year, 48/71 (67.6%) at 5 years, and 36/71 (50.7%) at 10 years. Freedom from hysterectomy for recurrent symptoms was 70/71 (98.6%) at 1 year, 60/71 (84.5%) at 5 years, and 51/71 (71.8%) at 10 years. Patient satisfaction with having UFE was a median of 5 on a scale of 1-5 (5 = very satisfied).
CONCLUSION: Women under 40 who undergo UFE are likely to experience return of symptoms before menopause and may require additional procedures, yet they remain highly satisfied with the procedure.
LEVEL OF EVIDENCE: Level 4, Case Series.